Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test the beneficial effects of rivastigmine
administration, and predict the treatment outcome with electroencephalography (EEG), in
patients with severe depression treated with electroconvulsive therapy (ECT). The study has
two main objectives:
- to study whether rivastigmine would ameliorate the side-effect profile of ECT
- to develop an outcome prediction model based on resting state EEG for both the response
to treatment as well as its side effect
Participants will be assessed by:
- Cognitive tests
- Questionnaires of clinical symptoms
- Questionnaires of depressive symptoms
- Bloodsample
- Resting state and task-based EEG
Researchers will compare patients with a depressive disorder treated with ECT receiving
rivastigmine to placebo patches to see if rivastigmine reduces cognitive side effects.
Phase:
Phase 4
Details
Lead Sponsor:
UMC Utrecht
Collaborators:
St. Antonius Hospital Tergooi Hospital ZonMw: The Netherlands Organisation for Health Research and Development